5068202025-10-012025-12-315068202025-04-012025-12-315068202025-10-012025-12-31in-capmkt:OtherExpenses1Member5068202025-10-012025-12-31in-capmkt:OtherExpenses2Member5068202025-10-012025-12-31in-capmkt:OtherExpenses3Member5068202025-04-012025-12-31in-capmkt:OtherExpenses1Member5068202025-04-012025-12-31in-capmkt:OtherExpenses2Member5068202025-04-012025-12-31in-capmkt:OtherExpenses3Member5068202025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15068202025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15068202025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares506820ASTRAZENNAINE203A01020ASTRAZENECA PHARMA INDIA LIMITEDMain BoardEquity2025-04-012026-03-312026-02-112026-01-31INRMillionsQuarterlyThird quarterSingle segmentHealthcare2026-02-1114:30:002026-02-1117:30:00Declaration of unmodified opinionfalsefalseThe same is not applicable to the Company.2025-10-012025-12-31UnauditedStandalone611570000051300000616700000006971200000-33073000009378000001060000038400000106570000057164000004506000001480000046540000040000000995000001395000000325900000000032590000010000032600000050000000213.0413.040013.0413.04 <BR> <BR> Notes: <BR> <BR> 1 The Statements of unaudited financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the “Act”) [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. <BR> 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. <BR> <BR> 3 During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company’s manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site had ceased and the Company is in the process of sale of assets related to the manufacturing site. <BR> 4 Pursuant to the notification by the Ministry of Labour & Employment on November 21, 2025 on the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as “the Labour Codes”), the Company has recognized provision towards past service cost on gratuity and compensated absences payable to employees amounting to Rs. 278.3 Million during the quarter ended December 31, 2025 which is included under “Employee benefit expense”. The Company will continue to monitor the finalisation of Central/ State Rules and clarifications from the Government in this regard and would provide appropriate accounting effect on the basis of such developments as needed. <BR> 5 Exceptional Items: <BR> a Exceptional items for the quarter ended 31 December 2025 and 31 December 2024 and year ended 31 March 2025 consists of expenses related to closure of the manufacturing site (Refer Note 3 above). <BR> b The exceptional items during the year ended 31 March 2025 and quarter ended 31 December 2024 also consists of employee separation cost amounting to Rs. 331.5 Million for restructuring of Biopharmaceuticals Business Unit in line with strategy of the Company to become a specialist focussed organisation, bring innovative medicines faster and transform patient outcome. <BR> 6 "This Statement of unaudited financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 11 February 2026. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter and nine months ended 31 December 2025. <BR> " <BR> <BR> By Order of the Board of Directors <BR> For AstraZeneca Pharma India Limited <BR> <BR> <BR> <BR> <BR> Place: Bengaluru Praveen Rao Akkinepally <BR> Date: 11 February 2026 Managing Director <BR> 2025-04-012025-12-31UnauditedStandalone16969700000225400000171951000009490000015471100000-57031000002186800000245000002298000002908800000152128000001982300000-4170000019406000004511000006310000051420000001426400000000014264000003200000142960000050000000257.0657.060057.0657.06Allowance for expected credit loss (net)12600000Selling, marketing and distribution expense358400000Other expenses694700000Allowance for expected credit loss (net)89200000Selling, marketing and distribution expense858700000Other expenses1960900000Re-measurement gains / (losses) on post employment benefit obligations100000100000Re-measurement gains / (losses) on post employment benefit obligations42000004200000010000001000003200000UnauditedtruePrice Waterhouse & Co Chartered Accountants LLPtrue2026-11-30